SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-22-008064
Filing Date
2022-11-28
Accepted
2022-11-28 17:13:29
Documents
17
Period of Report
2022-11-28
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT cns_8k.htm   iXBRL 8-K 64350
2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION O cns_ex0301.htm EX-3.1 7529
3 PRESS RELEASE cns_ex9901.htm EX-99.1 7930
7 GRAPHIC image_001.jpg GRAPHIC 177486
8 GRAPHIC image_002.jpg GRAPHIC 126283
9 GRAPHIC image_003.jpg GRAPHIC 4745
  Complete submission text file 0001683168-22-008064.txt   690817

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cnsp-20221128.xsd EX-101.SCH 3230
5 XBRL LABEL FILE cnsp-20221128_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE cnsp-20221128_pre.xml EX-101.PRE 22361
11 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3831
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 221426702
SIC: 2834 Pharmaceutical Preparations